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Abstract: 
  
Introduction 
 
Chronic rhinosinusitis (CRS) represents a common source of ill health; 11% of UK 
adults report CRS symptoms in a worldwide population study (1).  Symptoms, 
including nasal obstruction, nasal discharge, facial pain, anosmia and sleep 
disturbance, have a major impact on quality of life, reportedly greater in several 
domains of the SF-36 than angina or chronic respiratory disease (2). Acute 
exacerbations, inadequate symptom control and respiratory disease exacerbation 
are common problems faced by these patients (3, 4).  
 
CRS is a heterogeneous group of conditions, divided into two main phenotypic 
subgroups of those patients with and without nasal polyps. Unlike acute 
rhinosinusitis (ARS), CRS is not thought to have a primarily infectious aetiology; 
instead CRS is largely characterised by mucosal inflammation. Systemic 
antibiotics, therefore, probably have little role as antimicrobials in CRS 
management, with the exception of treating some acute exacerbations; NICE 
guidelines recommend withholding antibiotics in the majority of cases of 
uncomplicated ARS. The European Position Paper on Rhinosinusitis and Nasal 
Polyps (EPOS 2012) published treatment guidelines and a research strategy for 
CRS, emphasising where limited evidence restricts care (5), but there are 
currently no NICE guidelines for managing patients with RCS. Awareness and 
uptake of EPOS is variable, and both GPs and specialist ENT surgeons share 
uncertainty regarding the role of antibiotics(6). 
 
There is growing interest in immune-modulating effects of macrolide antibiotics 
in chronic airway inflammatory disease, with a low-dose long term macrolide 
being prescribed for its immune response and not primarily as an anti-bacterial 
agent (7). A 2016 Cochrane review by Head et al. compared systemic or topical 
antibiotic treatment to placebo, no treatment or other pharmacologic 
interventions, evaluated in RCTs with a follow‐up period of at least three months. 
The authors concluded that there was very little evidence that systemic antibiotics 
are effective in patients with CRS. They found moderate quality evidence of a 
modest improvement in disease‐specific quality of life in adults with CRS without 
polyps receiving three months of an oral macrolide, with a moderate improvement 
size (0.5 points on a 5‐point scale) seen only at the end of the three‐month 
treatment course of oral macrolides; by three months later, no difference was 
found (8). The authors concluded that more research is needed, especially 
regarding longer‐term outcomes and adverse effects.  
 
Longer-term antibiotic use in secondary care has a low-grade recommendation in 
EPOS reflecting conflicting evidence from 2 RCTs (9, 10) resulting in a call for 
further trials (8, 11-13). There are no NICE guidelines and uptake of EPOS is 
variable (6). A recent ENT-UK commissioning guideline (14) acknowledges the 
lack of high quality trials and  does not recommend routine antibiotic use for CRS 
in primary care. Despite this, CRS is said to account for 7.1% of primary care visits 
in the US where an antibiotic is prescribed (15), making it the  most common 
diagnosis associated with antibiotic usage in primary care. A previous study  
evaluated antibiotic prescribing for ‘rhinosinusitis’ in primary care, with 91% 
receiving an antibiotic prescription (16); however this study did not differentiate 
between acute and chronic rhinosinusitis. 
 
Antimicrobial stewardship describes measures aimed to improve the 
effectiveness and reduce the adverse effects of antimicrobial use, by reducing 
inappropriate antibiotic prescriptions, unsuitable use of broad-spectrum 
antibiotics and inappropriate dosage or duration use. This is driven by concerns 
of increasing antimicrobial resistance that is a major patient safety and public 
health concern as well as an economic issue (16, 17). Given the high prevalence of 
CRS, potentially high utilisation of antibiotics may represent a significant target 
for stewardship.  The aim of this study was to analyse rates of antibiotic usage in 
CRS in England and Wales and to identify trends in the choice of antibiotics 
prescribed. This study is part of the wider MACRO programme “Defining best 
Management of Adult patients with Chronic RhinOsinusitis” that aims to define 
best practice for treating and managing patients with CRS and will include an RCT 
to generate more evidence regarding the use of macrolides. 
 
 
Methods 
 
Data sources 
We used linked EHR from (1) primary care EHRs, with diagnoses coded using the 
Read controlled clinical terminology (Clinical Practice Research Datalink, 
CPRD(18)) from consenting general practices,  with (2) hospital care 
administrative records (Hospital Episode Statistics, HES diagnoses recorded using 
ICD-10 and procedures using OPCS-4). Phenotyping algorithms identifying 
disease status were created using the CALIBER approach described and validated 
elsewhere (18-20). Data were extracted from the CPRD GOLD (January 2017 
version).  
 
Eligibility 
The study period was 1st April 1997 to 29th February 2016. 
Male and female patients of 16 years of age and above, who were eligible for 
linkage to HES and ONS and had a minimum of one year of up-to-standard follow-
up in CPRD prior to entry in the cohort were eligible for inclusion in our study 
(where “up-to-standard” denotes a CPRD indication of research-quality data from 
the contributing general practice). Eligible patients were also required to have at 
least one day of up-to-standard information and data at an individual level 
deemed to be acceptable research quality by CPRD.  
 
Follow-up 
Follow-up began at the last of: the current registration date of the patient at their 
general practice, the up-to-standard date of the general practice or 1st April 1997, 
plus one year of up-to-standard follow-up data. If the patient’s 16th birthday came 
later, follow-up began at their 16th birthday.  
 
Follow-up ended at the first of: the date of the patient’s transfer out of the general 
practice, the last collection data of the general practice, date of death (recorded in 
either CPRD or ONS) or 29th February 2016 (study end date chosen to align with 
the HES linkage censoring date).   
 
Case ascertainment 
An EHR phenotype comprising primary care and secondary care diagnoses, and 
secondary care procedures deemed to indicate a definite diagnosis of chronic 
rhinosinusitis (CRS) cases was developed (see appendix 1). Patients with one or 
more of these diagnoses or procedures recorded during follow-up were 
considered to be definite CRS cases, with the date of diagnosis taken to be the date 
of the first such diagnosis or procedure. These patients had received a diagnosis 
code specifying CRS, or had undergone surgery for CRS. An example is the term 
“chronic maxillary rhinosinusitis” being recorded as the diagnosis code during a 
consultation was deemed to indicate a definite case of CRS. 
 
An EHR phenotype indicating primary or secondary care diagnosis terms and 
secondary care procedures deemed to indicate “very likely” or “likely” CRS 
diagnostic events was also developed (see appendix 1). Primary care symptoms 
were classified into four non-overlapping categories based on the European 
Position Paper on Rhinosinusitis and nasal Polyps (EPOS 2012) guidelines, 
representing: nasal obstruction, nasal discharge, change in sense of smell, and 
headache. A single primary care consultation in which the patient reported 
symptoms classed as either nasal obstruction or nasal discharge, and additionally 
reported symptoms classed in any of the three remaining symptom categories was 
taken to be a potential “very likely” CRS diagnostic event. As an example, a 
recorded code of “rhinosinusitis”, where chronicity was not specified was taken to 
be a potential “likely” diagnostic event, as we were unable to discern if the GP felt 
the episode was acute or chronic. 
 
Patients with no definite CRS diagnosis at any time during follow-up were deemed 
to be very likely CRS cases if they had two “very likely” CRS diagnostic events 
between three and nine months apart during follow-up. The first two events 
satisfying this condition were identified and the date of very likely CRS diagnosis 
taken to be the later date of the two events.  
 
Patients with no definite or very-likely CRS diagnosis at any time during follow-up 
were deemed to be likely CRS cases if they had either one “very likely” CRS 
diagnostic event and one “likely”, or two “likely” diagnostic events, between three 
and nine months apart during follow-up. The first two events satisfying this 
condition were identified and the date of likely CRS diagnosis taken to be the later 
date of the two events. 
 
Our resulting cohort contains all eligible patients who were classed as having a 
definite, very likely, or likely CRS diagnosis.   
  
Quantitative Variables 
 
Description of CRS cases:  
CRS definite, very likely and likely cases were described, by certainty of CRS 
diagnosis, in terms of the age (at diagnosis), gender, socioeconomic status and 
geographical profile, and polyp status.  Due to the limitations of the data, CRS cases 
were defined as “polyps present” or “polyps unknown”, the former representing a 
group where the presence of nasal polyps was recorded at some point in the 
patient journey.  
 
 
Antibiotic prescribing:  
“First-line” antibiotics were defined as any antibiotic prescribed on the day of CRS 
diagnosis, or within 5 days following diagnosis. Antibiotics were classed into: 
Cephalosporins, Metronidazole, Quinolones, Macrolides, Penicillins, 
Tetracyclines, or Other. Where multiple antibiotics were prescribed on the same 
day, these were classed as “multiple” antibiotics. Of patients prescribed first-line 
antibiotics, the proportion being prescribed each class was graphed by year of CRS 
diagnosis, overall, by certainty of CRS diagnosis, and by polyp status (ever during 
follow-up or not). The number of post-CRS diagnosis antibiotic prescriptions was 
tabulated overall, and by class of antibiotic. (Note: follow-up differs for different 
patients, so these numbers merely reflect what is in our data, rather than 
estimating a quantity such as “average number of prescriptions over 10 years”.) 
Second-line antibiotics were classed as the first other antibiotic prescription at 
any point (which may be of the same class as the first-line antibiotic).  
 
 
Statistical analysis 
Descriptive statistics were used to characterise the data. The estimated 
probability (95 % CI) of any antibiotic being given for any diagnosis within 2.5 
years was calculated as well as the estimated probability (95 % CI) of an antibiotic 
being given for CRS (defined as an antibiotic prescription issued within 5 days of 
a CRS-related consultation) within 2.5 years. Also the median time in months 
between the first and second antibiotic courses was calculated with interquartile 
ranges (25th – 75th percentile). 
 
Ethics 
Access to Clinical Practice Research Datalink (CPRD) data was granted following 
an Independent Scientific Advisory Committee (ISAC) application; Protocol 
number 16_200R. 
 
  
Results 
 
Identified CRS cases 
 
From the total of 88,317 cases of CRS identified, 71% were classified as definite, 
with 6.7% very likely and 22.4% likely. The details of the demographics are 
shown in Table 2 with a mean age of 51 and a slight female preponderance in the 
“definite” group.  
 
Descriptive data 
Antibiotic usage 
Within the total cohort of CRS cases identified, 40,462 (46%) had an antibiotic 
prescription within 5 days of their first CRS diagnosis (Table 2.1). This proportion 
varied considerably with the certainty of CRS diagnosis, with 29% of definite CRS 
cases receiving an antibiotic within 5 days of diagnosis, compared with 90% of 
likely cases.  
Of patients receiving a first line antibiotic within 5 days of CRS diagnosis, over 
80%, in each CRS group, received a subsequent prescription for an antibiotic (any 
type). This was not restricted to being within a certain time from the first 
prescription. For those patients who received a second antibiotic, the median time 
gap between the first and second prescriptions was 5.0 months overall, with the 
interquartile range varying from 1.6 to 12.4 months.  When restricted to 
prescriptions made within 5 days of a CRS-related consultation, 56.3% of cases 
received a subsequent prescription for an antibiotic. Patients followed for longer 
were more likely to have a second prescription; this can be overcome by 
estimating the probability of a subsequent antibiotic prescription assuming each 
patient was followed for a fixed period of time. Within 2.5 years of CRS diagnosis, 
84% were estimated to receive a subsequent prescription; 49% were estimated 
to receive a subsequent antibiotic prescription within 5 days of a CRS-related 
consultation. 
 
Approximately half of the CRS cases had no post-diagnosis antibiotic 
prescriptions, but 26% had more than 10 recorded prescriptions of antibiotics 
during follow-up, with some going into the hundreds (Table 2.1 and Figure 1a). 
Longer follow-up times are correlated with more prescriptions, ie  the number of 
prescriptions may simply be a measure of the duration of patients’ disease . Figure 
1b shows the expected distribution of numbers of antibiotic prescriptions within 
2.5 years of diagnosis, and within 5 years, assuming full follow-up over that period. 
Within 2.5 years of CRS diagnosis, approximately 85% of cases are estimated to 
have had at least two antibiotic prescriptions; 50% of cases are estimated to have 
had at least two antibiotic prescriptions within 5 days of a CRS-related 
consultation. Within 5 years of diagnosis, 61% of patients are estimated to have 
had 5 or more courses of antibiotics, and 9% are estimated to have had 5 or more 
antibiotics within 5 days of a CRS-related consultation.  
 
Figure 2 shows the number of antibiotic prescriptions during follow-up by class 
of the first antibiotic. So, for example, approximately 80% of patients prescribed 
penicillin as a first-line antibiotic were prescribed at least one additional course 
of penicillin during follow-up. Restricting the subsequent prescriptions to those 
within 5 days of a CRS-related consultation reduces this number to 45% of 
patients. For patients initially prescribed macrolides as a first-line antibiotic, 
approximately 25% had at least 5 prescriptions of macrolides during follow-up, 
5% had at least 5 of those prescriptions within 5 days of a CRS-related 
consultation. 
Figure 3 shows the duration of prescriptions.  The most common recorded 
duration of both macrolide and penicillin prescriptions are 1 week, with lower 
peaks at 5 days, 2, 4, and 8 weeks. One or more macrolide courses of 8+ weeks 
were received by 1,316 cases (2.1% of all CRS definite cases, 6.1% of those who 
received at least one macrolide prescription). One or more macrolides courses of 
2 or more weeks were received by 6,269 cases (9.9% of all CRS definite cases, 
28.8% of those who received at least one macrolide prescription).  
 
Trends over time in antibiotic prescribing 
With EHR data spanning almost 20 years, it was possible to discern clear trends in 
antibiotics prescriptions. Throughout this period, penicillins remained the first 
choice of antibiotic even when macrolide and tetracycline prescribing became 
more common, when all likelihood of CRS diagnosis was considered, with 
approximately 50% of our CRS cohort receiving this. However, in those with 
definite CRS, a clear increasing trend towards macrolide and tetracycline 
prescribing was evident. It is likely that two key agents that account for this trend 
are doxycycline and clarithromycin. The data showed an increasing trend in 
macrolides as a first line prescription; rising from 9% in 1998 up to 17% in 2015 
(Figure 4). Similarly, prescriptions of tetracyclines increased from 24% in 1998 to 
43%, and in 2015 tetracyclines were the most commonly prescribed antibiotic in 
CRS. In Figure 5, the differences in prescribing habits for first antibiotic 
prescription can be seen for the two main assumed phenotypes of CRS. In those 
where polyps were seen, trends showed penicillin prescriptions to be steady with 
tetracyclines declining and macrolides increasing; the opposite was true in those 
where the polyp status was unknown. 
Discussion 
 
This is the first study evaluating antibiotic usage for chronic rhinosinusitis in 
primary care in a UK setting. In our study, 45% of patients received antibiotics 
within 5 days of a consultation for CRS. The majority of patients in our cohort 
(71%) had a definite diagnosis of CRS (i.e. a Read or ICD-10 code specific for 
chronic disease); in this group only 29% received antibiotics within 5 days of a 
consultation for CRS. This suggests that in the majority of patients where the 
diagnosis of chronic disease is clear, antibiotics are not being prescribed, in 
keeping with EPOS guidelines (5). Of those who have received an antibiotic, it is 
still possible that the antibiotics have been prescribed for acute infective 
exacerbations, which can be frequent in CRS; recent qualitative interviews with 
primary care physicians, antibiotics were prescribed for acute exacerbations, 
purulent discharge and occasionally in response to patient pressure if antibiotics 
have been helpful in previous episodes(6).  
 
The remainder had ‘very likely’ or ‘likely’ diagnoses of CRS (for example, 2 
diagnoses of ‘rhinosinusitis’ more than 3 months apart but within 9 months). Our 
‘very likely’ and ‘likely’ cohorts include patients with 2 codes, more than 3 months 
apart, where the duration of sinusitis was not specified e.g. ‘Rhinosinusitis’ in 
contrast to CRS in our definite cohort. This may well reflect the uncertainty 
regarding chronicity of disease in the early stages; acute and chronic 
rhinosinusitis are differentiated in diagnostic criteria based on duration alone (i.e. 
less than or greater than 12 weeks(5)  and share common symptoms of nasal 
blockage, nasal discharge, facial pain and pressure and change in sense of smell. 
Antibiotic usage increased in those with ‘very likely’ CRS (77%) and with ‘likely’ 
CRS (89.5%). This almost certainly reflects greater uncertainty regarding whether 
the episode was thought to be an acute or chronic presentation; nonetheless, this 
would still suggest very high levels of antibiotic usage even in ARS, given NICE 
recommendations against.  
 
For patients who received an antibiotic at their first visit, more than 80% received 
a second course, with an average time of 5 months between courses. Within the 
whole CRS cohort, 16% of patients received more than 10 courses of antibiotics. 
Similar rates of repeat prescribing were demonstrated in all classes of antibiotics. 
Given the prevalence of CRS at 11% of UK adults, this suggests that, as in the US, 
antibiotic prescribing rates for CRS represent a very large burden in primary care, 
and a significant target for antibiotic stewardship. 
Macrolide antibiotics were more likely to be prescribed for longer duration than 
penicillins; among all CRS cases, 1,323 (2.1%) were prescribed at least one 
macrolide course of ≥8 weeks and 6,269 (10.0%) were prescribed a macrolide 
course of ≥2 weeks. Restricting attention to the 21,549 CRS definite patients 
prescribed at least one macrolide, 1,323 (6.1%) received at least one macrolide 
prescription of ≥8 weeks and 6,269 (29.1%) received at least one macrolide 
prescription of ≥2 weeks. The UK Commissioning guidance for CRS advises against 
use of long term macrolides in primary care (14). Contrary to this guidance, 12% 
of CCGs were found to make a recommendation to prescribe long term macrolide 
antibiotics to patients with symptoms suggestive of CRS prior to referral to 
secondary care (21). The use of a prolonged course in primary care may therefore 
reflect local commissioning policies, although it may also occur on 
recommendation from secondary care after a more extensive investigation. We 
agree with the recommendation by Ferguson et al (22) that there should be a 
moratorium on the use of long-term courses of macrolide antibiotics in ‘presumed’ 
CRS, and use should be restricted to secondary care after confirmation of the 
diagnosis with objective findings such the endoscopic and/or radiological findings 
required by the EPOS guidelines (5). 
 
When looking at trends in first-line antibiotic choices over the last 20 years, 
overall rates of prescribing appear stable but there has been an increase in the use 
of both macrolides and tetracyclines (predominantly doxycycline), particularly in 
the CRS definite cases; although they appear to have been prescribed for the 
opposite CRS subgroup than recommended. NICE guidelines for ARS recommend 
penicillins as their first choice, and recommend doxycycline and macrolides only 
in cases of penicillin allergy. In secondary care, EPOS recommends for selected 
patients with CRS with nasal polyps, and as above, macrolides in selected patients 
with CRS without polyps and normal IgE levels (5, 23). The effectiveness of 
doxycycline has only been evaluated in one short-term RCT (24) and a small open 
label study (25) to date in patients with with polyps, showing moderate benefit in 
terms of reduction of polyp size compared with placebo, but in terms of symptom 
control was only found to reduce postnasal drip and not other nasal symptoms. 
Lack of access to endoscopy will severely restrict the ability to differentiate 
between CRS with and without polyps in primary care, and may account for the 
trend of increasing use of macrolides in patients with polyps and tetracyclines in 
CRS patients without polyps – in contradiction to recommended practice.  
The changes in patterns over time are likely to reflect trends in secondary care 
driving primary care prescribing habits. It is evident that both ENT and primary 
care doctors would benefit with support in applying evidence-based care in CRS, 
in addition to further research to establish the true role of antibiotics in the 
management of CRS. This observational study has been carried out as part of the 
MACRO Programme that involves a randomised controlled trial that will include a 
12-week course of clarithromycin in patients with CRSwNPs and CRSsNPs. 
 
Limitations of this study 
We are likely to be underestimating overall antibiotic usage in CRS, as secondary 
care prescribing is not captured in our electronic health records, and may be as 
high as in primary care. It is also possible that antibiotics have been prescribed for 
CRS without a diagnostic code being recorded, and therefore primary care 
prescribing likely lies between the rates of antibiotics linked within 5 days of a 
CRS code and for all diagnoses – we have therefore presented both rates in our 
analysis. We must rely on the diagnostic codes recorded and are unable to verify 
the diagnosis of CRS in any of our patients with endoscopy or CT scanning. The 
majority of patients in our cohort had ‘definite’ CRS; however, they may have 
presented with an acute exacerbation. Our assumptions in creating our very likely 
and likely cohorts may be incorrect, and this group may include patients with ARS, 
allergic rhinitis and other related conditions.  
Conclusions 
Based on current evidence and guidelines, antibiotics are not routinely 
recommended for the treatment of CRS, and even in the setting of acute 
exacerbations, their value remains unclear. In this study we have found high levels 
of antibiotic prescribing in patients with ‘likely’ and ‘very likely’ CRS in primary 
care; although this probably reflects the diagnostic uncertainty around CRS in that 
setting and may represent a response to assumed acute exacerbation. While the 
majority of patients with a definite diagnosis of CRS did not receive an antibiotic 
prescription, there remains a high level of repeat antibiotic prescribing; in 
particular, over 1 in 7 patients received more than 10 prescriptions for antibiotics. 
Nearly 1 in 2 patients who received a macrolide antibiotic prescription were given 
a prolonged course of greater than 2 weeks. Use of antibiotics in patients with CRS 
in primary care appears to be an important potential target for antimicrobial 
stewardship that has been so far overlooked.  
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Tables 
 
Table 1.1. CRS cases identified according to grouping  
CRS diagnosis certainty Frequency % 
Definite 62,685 71.0 
Very likely 5,883 6.7 
Likely 19,749 22.4 
 
Table 1.2. Demographics by CRS grouping 
 CRS definite 
(n=62,685) 
CRS very likely 
(n=5,883) 
CRS likely 
(n=19,749) 
 Freq % Freq % Freq % 
Age (yrs; mean (SD)) 51.0 (16.2) 49.3 (16.3) 47.4 (15.3) 
Sex       
   Male 29,306 46.8 1,451 24.7 4,292 21.7 
   Female 33,379 53.2 4,432 75.3 15,457 78.3 
Ethnicity (HES) 
   White 49,725 79.3 1,073 18.2 3,105 15.7 
   Indian subcontinent 1,114 1.8 21 0.4 67 0.3 
   Black 642 1.0 7 0.1 19 0.1 
   China/SE Asia 450 0.7 2 0.0 18 0.1 
   Mixed 830 1.3 8 0.1 44 0.2 
   Unknown 9,924 15.8 4,772 81.1 16,496 83.5 
Index of Multiple Deprivation 
   1(least deprived) 16,124 25.7 1,586 27.0 5,407 27.4 
   2 14,529 23.2 1,253 21.3 4,647 23.5 
   3 13,007 20.7 1,285 21.8 4,094 20.7 
   4 10,761 17.2 930 15.8 3,239 16.4 
   5 (most deprived) 8,184 13.1 824 14.0 2,351 11.9 
   Missing 80 0.1 5 0.1 11 0.1 
Practice region  
  North East 1,520 2.4 33 0.6 300 1.5 
  North West 10,710 17.1 1,317 22.4 2,840 14.4 
  Yorkshire & the 
Humber 
2,701 4.3 141 2.4 1,144 5.8 
  East Midlands 1,774 2.8 238 4.0 694 3.5 
  West Midlands 7,931 12.7 903 15.3 2,112 10.7 
  East of England 6,927 11.1 1,329 22.6 2,282 11.6 
  South West 7,575 12.1 534 9.1 2,433 12.3 
  South Central 7,965 12.7 682 11.6 3,203 16.2 
  London 7,851 12.5 399 6.8 2,054 10.4 
  South East 7,731 12.3 307 5.2 2,687 13.6 
Polyps known to be 
present 
23,960 38.2 133 2.3 303 1.5 
Post-CRS-diagnosis 
follow-up (yrs), median 
(25th, 75th percentile) 
5.1 (2.3, 
9.2) 
6.3 (2.9, 
10.5) 
5.2 (2.4, 9.1) 
Table 2.1a: First and second line antibiotic prescribing where “for CRS” refers to those prescribed within 5 days of a CRS-related consultation  
  
 Definite 
(n=62,685) 
Very likely 
(n=5,883) 
Likely 
(n=19,749) 
All 
(n=88,317) 
 Freq % Freq % Freq % Freq % 
Antibiotic prescribed within 5 days of CRS 
diagnosis 
18,232 29.1 4,542 77.2 17,688 89.6 40,462 45.8 
Subsequent antibiotic given 15,242 83.6 4,080 89.8 15,627 88.3 34,949 86.4 
Estimated probability (95 % CI) of any antibiotic 
within 2.5 years 
 80.0 
(79.5, 80.7) 
 88.0 
(86.9, 89.0) 
 87.8 
(87.3, 88.4) 
 84.4 
(84.0, 84.7) 
Subsequent antibiotic given for CRS 8,957 49.1 2,990 65.8 10,843 61.3 22,790 56.3 
Estimated probability (95 % CI) of an antibiotic 
being prescribed for CRS within 2.5 years 
 42.3 
(41.5, 43.1) 
 57.1 
(55.6, 58.6) 
 54.5 
(53.7, 55.2) 
 49.3 
(48.8, 49.8) 
Time in months between first and second antibiotic (median (25th – 75th percentile)) 
Any second antibiotic 5.4 (1.7, 14.2) 4.4 (1.6, 11.1) 4.8 (1.6, 11.3) 5.0 (1.6, 12.4) 
Second antibiotic for CRS 9.4 (2.7, 24.5) 9.2 (3.0, 22.8) 9.9 (3.4, 23.5) 9.6 (3.0, 23.8) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2b: Total number of antibiotic prescribing episodes by CRS group 
 
 Definite 
(n=62,685) 
Very likely 
(n=5,883) 
Likely 
(n=19,749) 
All 
(n=88,317) 
Overall total number of antibiotic prescribing episodes: 
            0 10,979 17.5 239 4.1 370 1.9 11,588 13.1 
            1 9,237 14.7 597 10.1 2,342 11.9 12,176 13.8 
            2          6,717 10.7 519 8.8 2,005 10.2 9,241 10.5 
            3 5,210 8.3 449 7.6 1,734 8.8 7,393 8.4 
            4 4,234 6.8 396 6.7 1,461 7.4 6,091 6.9 
            5 3,332 5.3 344 5.8 1,304 6.6 4,980 5.6 
          >5 22,976 36.7 3,339 56.8 10,533 53.3 36,848 41.7 
Total number of antibiotic prescribing episodes for CRS: 
            0 30,536 48.7 816 13.9 1,151 5.8 32,503 36.8 
            1 15,884 25.3 1,777 30.2 7,228 36.6 24,889 28.2 
            2  6,196 9.9 974 16.6 3,911 19.8 11,081 12.5 
            3 3,126 5.0 585 9.9 2,368 12.0 6,079 6.9 
            4 1,817 2.9 435 7.4 1,480 7.5 3,732 4.2 
            5 1,228 2.0 299 5.1 1,006 5.1 2,533 2.9 
          >5 3,898 6.2 997 16.9 2,605 13.2 7,500 8.5 
Figures 
Figure 1a: Overall number of antibiotic prescriptions following CRS diagnosis.  
 
 
 
Figure 1b: Expected distribution of antibiotic prescriptions at 2.5 and 5 years 
post CRS diagnosis.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Number of antibiotic prescriptions following CRS diagnosis, by class 
of initial first-line antibiotic  
 
 
 
Figure 3: Duration of prescription given for macrolide and penicillin courses 
used in primary care among CRS definite cases following their CRS definite 
diagnosis. 
 
 
Figure 4. Trends in antibiotic prescribing by CRS diagnosis certainty 
 
 
 
Figure 5: First-line antibiotic by polyp status 
 
 
